Pfizer’s $11.6B wager; TIGIT implosion; An unusual pharma-biotech pact; Inside a16z’s vision to reshape biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Are you headed to the BIO confab in San Diego next month? If so,…

Click here to view original post